Please login to the form below
epilepsy
This page shows the latest epilepsy news and features for those working in and with pharma, biotech and healthcare.
WHO publishes brief calling for integrated approach to epilepsy treatment
Epilepsy affects over 50 million people globally and accounts for 125, 000 death per year. ... It also reinforces a call to strengthen services, while promoting a patient-centric, human rights approach in order to fully meet the epilepsy community’s
Latest news
-
Why diverse and inclusive teams are the powerhouses of innovation
Erin wanted each short to focus on a single aspect of dealing with epilepsy as an adolescent. ... Erin said: “At first, I didn’t want to face up to having epilepsy, and definitely didn’t want to talk about it.
-
NHS to roll out brain laser therapy for epilepsy patients
The fibre optic laser requires a 1.5mm-wide probe into the skull and destroys the brain tissue which causes epilepsy from the inside by using heat. ... to control their seizures and will give those with epilepsy a real chance to live a normal life.
-
COVID-19 linked to long-term neurologic disorders in new US study
Those who had had COVID-19 were also 80% more likely to experience epilepsy or seizures, 50% more likely to have an ischaemic stroke, 43% more likely to have mental health
-
COVID-19 linked to higher risk of brain fog, dementia and psychosis in new study
cognitive deficit, dementia and epilepsy or seizures, which persisted throughout. ... have an increased risk of cognitive deficit, insomnia, intracranial haemorrhage, ischaemic stroke, nerve, nerve root, plexus disorders, psychotic disorders and epilepsy
-
WHO publishes first position paper on optimising brain health
brain health. WHO also outlines that optimising brain health is ‘central to achieving global commitments outlined in the Intersectoral global action plan on epilepsy and other neurological disorders 2022–2031,
More from news
Approximately 34 fully matching, plus 188 partially matching documents found.
Latest Intelligence
-
Maintaining continuity of care in Ukraine as conflict continues
This included 30 million daily treatments for diabetes, cardiovascular disease, epilepsy and other life-threatening and chronic conditions.
-
New thinking, bold action: building a better future for people living with severe diseases
For people living with severe neurological conditions like epilepsy, the struggles of the past year were multiplied. ... We recently announced our investment in the launch of Nile AI, a new independent company created to develop an epilepsy care
-
The changing nature of approvals – what does the future hold?
Therapeutics to focus on therapies for Parkinson’s, epilepsy and other central nervous system disorders.
-
Growing up as a patient is hard to manage
For example, studies show that approximately 38% of adolescents with epilepsy are non-adherent, whereby this increases to approximately 50% of adolescents with asthma reported as failing to take prescribed doses
-
Strengthening business competition and reducing anti-competitive practices
One of the largest was the £84.2m fine against Pfizer in 2016 for its 2, 600% price increase on an anti-epilepsy drug supplied to the NHS.
More from intelligence
Approximately 1 fully matching, plus 14 partially matching documents found.
Latest appointments
-
GW Pharmaceuticals strengthens research and development team
look forward to building on the progress of the Epidiolex programme in treatment resistant forms of epilepsy.”. ... science to provide breakthroughs not only in epilepsy but across a range of disease areas.
-
Turing names Eliseo Salinas as head of R&D
epilepsy, stroke, Parkinson's, attention deficit disorder and Alzheimer's disease.
-
GW hires Pfizer’s Kenneth Sommerville
in epilepsy, pain and other diseases.
-
Acorda appoints new CFO
This growth is led by six therapies in clinical studies that address a range of disorders including post-stroke deficits, epilepsy, cerebral palsy, stroke, peripheral nerve damage, spinal cord injury, neuropathic
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Lifesaving QR Code Wearable Launched to Help Emergency Services
We all know someone vulnerable, and people with conditions such as diabetes, epilepsy, and dementia could benefit from medical interventions during those critical moments.
-
OPEN VIE is awarded a Bronze Award at the PM Society Digital Awards 2020
Addressing the inequality in access to Vagus Nerve Stimulation (VNS) Therapy to treat patients with Epilepsy entailed identifying delays in referrals and treatment, showing improvements in outcomes and stratifying patients suited
-
War on drugs: the use of controlled substances in medicine
It has shown promise in mental health conditions, skin conditions and a cannabis-based medicine is now available on the NHS for the treatment of epilepsy.
-
Lucid Group welcomes new magical talent and boosts their medical writing teams with hires in the US and UK
With three years’ healthcare communications experience, and a wealth of knowledge in epilepsy, immunotherapy and oncology Andrew comments, “I have had a very fulfilling first two months at Lucid; the team
-
Rare Disease Day 2018: Five things you should know about rare diseases.
some types of epilepsy are reported to affect about 100 families [9]).
More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Roche’s Polivy recommended by NICE for lymphoma therapy
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- ASH 2022: bad blood but big advances
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- Gilead’s Trodelvy approved by FDA for metastatic breast cancer
- World Health Organization releases new road map for breast cancer
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- Making new year resolutions that can also benefit others
- AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
- ICR calls for improved biomarker cancer tests to help personalise treatment
- Omnichannel communications in Medical Affairs: closing the gap between aspiration and reality
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Meeting healthcare’s rising challenges
- Why female mentorship is so powerful in pharma
- AZ’s COVID-19 vaccine trial to continue after Brazilian volunteer death
PMHub
Aptus Health
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...
Latest intelligence
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
- Pharmaceutical Marketing Strategies For The Digital Age
- In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...
